Gsk Share Discussion Threads

[zeppo] 18/5/2021 09:26

abdulla

Re 26615;

This share price drop indicates that the investors are not happy with Elliots, they would rather keep things as they are.

Shareholders seldom benefit from selling the businesses income streams.

As a Whitbread shareholder I got nothing from the sale of Costa: other than a massively reduced share price.

Fullers sold their London brewery on valuable real estate.


Fullers languishes.


A reduced dividend is forecast for GSK.

The dividend has bee the same for many tears now.

It has been difficult for them to keep paying it but why lose an income stream in order to speculate on drug research?


It is highly speculative that we will gain anything from the move.

[abdullla] 18/5/2021 09:07

Alex I am taking about investors who think otherwise,I still think that Elliots,if true are just trying their luck as they have failed to make a genuine public statement.

[alex1621] 18/5/2021 08:55

I thought Elliot was fake news, Abdulla?

[xxxxxy] 18/5/2021 08:52

The human body normally contains about 30 trillion bacterial cells. The human body effectively deals with this until such a time in old age the body biochemistry is breaking down anyway and the body dies.This not a Pandemic as not all age groups are dying and most death confined to groups such as elderly.  Some small number of deaths in specific groups does not constitute a Pandemic.But Health Security is now a major consideration for governments. And so GSK. https://en.m.wikipedia.org/wiki/Human_microbiome#:~:text=As%20of%202014%2C%20it%20was,and%20that%20an%20adult%20human

[xxxxxy] 18/5/2021 08:49

GlaxoSmithKline (GSK.L) reported a second set of optimistic results in its coronavirus vaccine trials in as many days on Tuesday, saying it had seen "positive interim phase 2 clinical trial safety and immunogenicity data" in its link-up with Medicago. Its vaccine candidate has produced a similar antibody response in adults and in the elderly after two doses, it said. It also said that neutralising antibody responses were ten times higher than in people recovering from COVID-19. Alongside this, no related severe adverse events have been reported in conjunction with the trials. GSK is a FTSE 100 (^FTSE) drugs giant worth about £69bn ($97bn) and employing 94,000 people.Despite its size, it has been something of a laggard in the race to produce a coronavirus vaccine, with several other candidates moving to mass-production and worldwide rollout first, including Pfizer (PFE), the Oxford-AstraZeneca (AZN.L) effort and Moderna (MRNA)."These results give us confidence as we continue to move forward with our Phase 3 clinical trial. We hope to add another tool in the global fight against COVID-19, particularly as cross-protection emerges as an important consideration in vaccination efforts worldwide," said Nathalie Landry, executive vice-president, scientific and medical affairs at Medicago.Read more: FTSE rises as UK unemployment rate falls amid signs of recoveryOn Monday, GSK and Sanofi (SNY) reported strong results, saying the jab it is developing had "triggered strong neutralising antibody responses in all adult age groups.""Overall, the vaccine candidate elicited strong neutralising antibody levels that were comparable to those generated by natural infection, with higher levels observed in younger adults (18 to 59 years old)," it said.Phase 3 trials are expected to start in the coming weeks.The phase 3 trial is expected to enrol more than 35,000 adult participants from a broad range of countries and will assess the efficacy of two vaccine formulations including the D614 (Wuhan) and B.1.351 (South African) variants..... Yahoo Finance

[spoole5] 18/5/2021 08:45

Or that they don't have confidence to implement the necessary measures

[abdullla] 18/5/2021 08:42

This share price drop indicates that the investors are not happy with Elliots, they would rather keep things as they are .

[montyhedge] 18/5/2021 07:28

Don't worry end the day blue and 100% guaranteed to be up tomorrow.

[spoole5] 18/5/2021 07:27

Market up gsk down. Perennial underperformer, Emma will be to blame when this gets ripped to pieces

[abdullla] 18/5/2021 07:09

A lot of selling before the war starts.

[spoole5] 18/5/2021 07:02

Good to hear the language coming from elliott, this needs completely breaking up and selling off to realise full value for shareholders.

[notbitcoin] 18/5/2021 06:50

Plenty of good news coming .
She needs it .To fight off rebellion

[tradermichael] 18/5/2021 06:50

That was a quick response, monty!

[montyhedge] 18/5/2021 06:48

Ex div Thursday should be through 1400p by then. 19p in the tax free isa bag, I don't think a 19p drop, more like 12p on Thursday.

[tradermichael] 18/5/2021 06:47

First: GSK and France's Sanofi said their potential Covid-19 vaccine – which was delayed by a mishap – triggered strong immune responses in all adult age groups in preliminary trials, boosting optimism the shot may join the fight against the pandemic this year.

Second: GlaxoSmithKline and Medicago Covid-19 vaccine gets positive interim phase 2 results

What chance, now, of a 19p drop on Thursday with all this good news??

[philanderer] 17/5/2021 23:42

Game on, sides being taken ;-)


"Top investor fires warning shot at GSK boss Walmsley as she prepares to fight off Wall Street raiders: Jury is still out on her future, declares Aviva"

[whatsup32] 17/5/2021 16:09

Took my small profit and bought RR instead. If as expected routes to US open from EU it should move north from here

[abdullla] 17/5/2021 14:17

I am sure Elliots will fix it for us !

[tradermichael] 17/5/2021 14:06

The 'top 20' shareholders would express support, wouldn't they - after all they still hang on to their old school tie.

[abdullla] 17/5/2021 13:56

GlaxoSmithKline Gets Support From Leading Shareholders Over Elliott Management Shake-Up Bid -The TimesSource: Dow Jones News--GlaxoSmithKline PLC shareholders have backed the company over concerns that activist U.S. hedge fund Elliott Management is set to push for a shakeup, The Times reports.--Several top 20 shareholders in the British pharmaceutical company have contacted Chairman Jonathan Symonds to express support for the board and its current strategy, according to The Times.--Elliott hasn't yet revealed its intentions to the company but has begun to engage with other leading shareholders, The Times reports. Full story: https://bit.ly/3hDWgn8

[montyhedge] 17/5/2021 13:39

Ex div Thursday nice 19p in the isa bag tax free.

[montyhedge] 17/5/2021 12:36

GSK I see straight through 1400p before ex div date.

[montyhedge] 17/5/2021 11:36

Glen
Thats a rubbish stock.

[mcflies] 17/5/2021 11:25

expect the 19p drop on Thursday.